On December 27, 2017, Isodiol International Inc. (CNSX:ISOL) closed the transaction. On the same date, the company announced that it issued 8,080,000 units at a price of CAD 1.25 per unit for proceeds of CAD 10,100,000 in second tranche of the transaction. The transaction included participation from Scythian Biosciences Corp.

(TSXV:SCYB) and Liberty Health Sciences Inc. (CNSX:LHS). The company issued a total of 24,080,000 units for total gross proceeds CAD 30,100,000 in the transaction. The company paid finder's fees of CAD 1,806,000.